GMT GenomicsS.A.
Research and experimental development in natural sciences and engineering
Overview
Gmt Genomics is the creator of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. They have developed the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which is designed to detect viruses and bacteria responsible for respiratory tract infections and is the only solution of its kind in Europe. The company is also involved in technology trials and M&A efforts in Asia related to their diagnostic devices.
Financials
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Miron Tokarski to appear in upcoming webinar “Meeting the Challenges and Unlocking the Potential of Point-of-Care Molecular Diagnostics”
Another patent granted. Another step in building global protection of Genomtec molecular diagnostics technology
Genomtec secured 11 million PLN from share issue for finalizing global M&A strategy and commercialization of breakthrough Genomtec ID and OncoSNAAT® technologies
Start of Genomtec public share offering to raise funds for finalizing M&A process and commercialization of Genomtec ID and OncoSNAAT® technologies
Genomtec plans share issue. Funds will support M&A process and project commercialization. Company signed investment agreement with key shareholder.
Genomtec prepares to test its technology with potential partners in Asia as part of M&A process
Industry
Bank accounts
Registered as a VAT taxpayer on 2025-11-01. Active
26 1090 2398 0000 0001 6486 6619- 44 1090 2398 0000 0001 6486 6586
- 65 1090 2398 0000 0001 6186 7744
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board independently.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 1,100,000 | $297,136.68 | 100% | |
| — | — | 0% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Miron Tokarski (36)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). | |
Michał Wachowski (44) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Scope FluidicsS.A. | $4,660,220.99 | scopefluidics.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| GenxoneS.A. | $665,361.35 | genxone.eu | ||
| MedisensonicS.A. | $362,572.63 | medisensonic.com | ||
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| GenomtecS.A. | $47,965.85 | genomtec.com | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| Micropurasp. z o.o. | $12,556.50 | micropura.eu |
FAQ
Last updated: 2026-09-15